University of Washington spinout Icosavax has filed for an initial public offering on the Nasdaq Global Select Market, with financial terms yet to be set.
Icosavax, a US-based vaccine developer based on research at University of Washington (UW), filed for an initial public offering on Tuesday with a $100m placeholder target.
The company hopes to list on the Nasdaq Global Select Market under the symbol ICVX. It has not yet set any terms for the proposed offering.
Founded in 2017, Icosavax is working on vaccines for infectious diseases that cause life-threatening respiratory illnesses. Its pipeline includes IVX-A12 and IVX-411, candidates aimed at…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
